Please login to the form below

MDR

This page shows the latest MDR news and features for those working in and with pharma, biotech and healthcare.

FDA green lights study of phage-based drug for resistant infections

One company working in this area – Adaptive Phage Therapeutics – has just won FDA approval to start human testing of personalised bacteriophage therapeutics for serious MDR infections. ... strain. Arms of the study will also focus on specific bacteria

Latest news

Merck preps regulatory filings for much-needed antibiotic combo

An independent UK review estimated that by 2050 MDR infections could claim 10 million lives a year and result in a cumulative loss from global output of $100trn. ... rates of multidrug resistant (MDR) strains, the need for new treatment options is
Pharma must do more on antibiotic resistance, Davos meeting hears

In particular, more needs to be done to bring forward new drugs for multidrug resistant (MDR) pathogens or ‘superbugs’ - there are currently 28 novel drugs for high-priority pathogens in phase
Pfizer launches antibiotic resistance surveillance website

Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn
Pfizer launches new antibiotic Zavicefta in UK and Germany

MDR infections are an increasing global threat," said Matteo Bassetti, chief of the infectious diseases Clinic at University of Udine in Italy. ... The availability of Zavicefta is a major step forward for physicians faced with the challenge of treating
AZ slims down again with sale of antibiotics to Pfizer

ATM-AVI is in trials for life-threatening Gram-negative bacterial infections caused by multi-drug resistant (MDR) strains, while CXL has activity against MDR Gram-positive and Gram-negative pathogens.

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Medical device regulation - a risk-based approach to compliance

Simply put, complying with MDR is another stressor for medtechs at an already challenging time, potentially affecting both top- and bottom-line growth. ... It's difficult to estimate just how great the costs associated with MDR implementation will

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

Medical Device Clinical Trials 2020

In this session, we heard from Bassil Akra, CEO of QUnique Group, who gave us a quick overview of the EU MDR. ... We’re pleased to hear that not only the pharma industry will benefit from the EU MDR, but there will be positive changes for patients too.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....